Ulcerative colitis

Inflammatory bowel disease (IBD) [DS:H01227]

Ulcerative colitis (UC) is one subtype of inflammatory bowel disease (IBD) whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. In UC the inflammatory is limited to the musoca of the colon and rectum. Clinically, the most common manifestation of UC may include bloody diarrhea, abdominal pain. In most severe cases, patients may experience fever, weight loss, anemia, and the intestine can get distended, presenting deep ulceration and possibly intestinal perforation.The long-time duration of the disease increases a colorectal caner risk. UC is associated with a Th2 immune response. Recent genetic analyses have linked genes including interleukin 23 receptor, interleukin 10 and macrophage stimulating 1.

Immune system disease

IL23R (polymorphism) [HSA:149233] [KO:K05065]
IL10 (polymorphism) [HSA:3586] [KO:K05443]
MST1 (polymorphism) [HSA:4485] [KO:K23441]

Fusobacterium varium [GN:fva]

Triamcinolone acetonide [DR:D00983]
Dexamethasone [DR:D00292]
Dexamethasone sodium phosphate [DR:D00975]
Hydrocortisone [DR:D00088]
Hydrocortisone acetate [DR:D00165]
Hydrocortisone sodium succinate [DR:D00978]
Prednisolone [DR:D00472]
Prednisolone sodium phosphate [DR:D00981]
Prednisone [DR:D00473]
Budesonide [DR:D00246]
Sulfasalazine [DR:D00448]
Mesalamine [DR:D00377]
Olsalazine sodium [DR:D00727]
Balsalazide disodium [DR:D02715]
Methylprednisolone [DR:D00407]
Methylprednisolone sodium succinate [DR:D00751]
Methylprednisolone acetate [DR:D00979]
Cortisone acetate [DR:D00973]
Vedolizumab [DR:D08083]
Infliximab [DR:D02598]
Adalimumab [DR:D02597]
Golimumab [DR:D04358]

PMID:26339135 (description and drug)

de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.

Mediators Inflamm 2015:493012 (2015)
DOI:10.1155/2015/493012

PMID:19923578

Abraham C, Cho JH

Inflammatory bowel disease.

N Engl J Med 361:2066-78 (2009)
DOI:10.1056/NEJMra0804647

PMID:18048021

Pang YH, Zheng CQ, Yang XZ, Zhang WJ

Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients.

Cell Immunol 248:115-20 (2007)
DOI:10.1016/j.cellimm.2007.10.003

PMID:18836448

Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S

Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.

Nat Genet 40:1319-23 (2008)
DOI:10.1038/ng.221

PMID:26600980 (drug)

Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H

Promising biological therapies for ulcerative colitis: A review of the literature.

World J Gastrointest Pathophysiol 6:219-27 (2015)
DOI:10.4291/wjgp.v6.i4.219

PMID:26284562 (drug)

Danese S, Vuitton L, Peyrin-Biroulet L

Biologic agents for IBD: practical insights.

Nat Rev Gastroenterol Hepatol 12:537-45 (2015)
DOI:10.1038/nrgastro.2015.135